Home
/
Sarepta Therapeutics, Inc.
/
Financials
/
Quarterly
Sarepta Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Sarepta Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$399.36M
Nov 6, 2025
Q2
2025
Jun 30, 2025
$611.09M
Aug 6, 2025
Q1
2025
Mar 31, 2025
$744.86M
May 6, 2025
Q3
2025
Sep 30, 2024
$467.17M
Nov 6, 2025
Q2
2025
Jun 30, 2024
$362.93M
Aug 6, 2025
Q1
2025
Mar 31, 2024
$413.46M
May 6, 2025
Q3
2024
Sep 30, 2023
$331.82M
Nov 6, 2024
Q2
2024
Jun 30, 2023
$261.24M
Aug 7, 2024
Q1
2024
Mar 31, 2023
$253.50M
May 1, 2024
Q3
2023
Sep 30, 2022
$230.27M
Nov 1, 2023
Q2
2023
Jun 30, 2022
$233.49M
Aug 2, 2023
Q1
2023
Mar 31, 2022
$210.83M
May 2, 2023
Q3
2022
Sep 30, 2021
$189.41M
Nov 2, 2022
Q2
2022
Jun 30, 2021
$164.09M
Aug 2, 2022
Q1
2022
Mar 31, 2021
$146.93M
May 4, 2022
Q3
2021
Sep 30, 2020
$143.92M
Nov 3, 2021
Q2
2021
Jun 30, 2020
$137.36M
Aug 4, 2021
Q1
2021
Mar 31, 2020
$113.67M
May 5, 2021
Q3
2020
Sep 30, 2019
$99.04M
Nov 5, 2020
Q2
2020
Jun 30, 2019
$94.67M
Aug 5, 2020
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$370.04M
Nov 6, 2025
Q2
2025
Jun 30, 2025
$513.12M
Aug 6, 2025
Q1
2025
Mar 31, 2025
$611.52M
May 6, 2025
Q3
2025
Sep 30, 2024
$429.77M
Nov 6, 2025
Q2
2025
Jun 30, 2024
$360.55M
Aug 6, 2025
Q1
2025
Mar 31, 2024
$359.48M
May 6, 2025
Q3
2024
Sep 30, 2023
$309.32M
Nov 6, 2024
Q2
2024
Jun 30, 2023
$238.99M
Aug 7, 2024
Q1
2024
Mar 31, 2023
$231.50M
May 1, 2024
Q3
2023
Sep 30, 2022
$207.77M
Nov 1, 2023
Q2
2023
Jun 30, 2022
$211.24M
Aug 2, 2023
Q1
2023
Mar 31, 2022
$188.83M
May 2, 2023
Q3
2022
Sep 30, 2021
$166.91M
Nov 2, 2022
Q2
2022
Jun 30, 2021
$141.84M
Aug 2, 2022
Q1
2022
Mar 31, 2021
$124.93M
May 4, 2022
Q3
2021
Sep 30, 2020
$121.43M
Nov 3, 2021
Q2
2021
Jun 30, 2020
$111.34M
Aug 4, 2021
Q1
2021
Mar 31, 2020
$100.45M
May 5, 2021
Q3
2020
Sep 30, 2019
$99.04M
Nov 5, 2020
Q2
2020
Jun 30, 2019
$94.67M
Aug 5, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($179.95M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
$196.89M
Aug 6, 2025
Q3
2025
Jun 30, 2025
$196.89M
Nov 6, 2025
Q2
2025
Mar 31, 2025
($447.51M)
Aug 6, 2025
Q1
2025
Mar 31, 2025
($447.51M)
May 6, 2025
Q3
2025
Mar 31, 2025
($447.51M)
Nov 6, 2025
Q3
2025
Sep 30, 2024
$33.61M
Nov 6, 2025
Q2
2025
Jun 30, 2024
$6.46M
Aug 6, 2025
Q3
2025
Jun 30, 2024
$6.46M
Nov 6, 2025
Q1
2025
Mar 31, 2024
$36.12M
May 6, 2025
Q2
2025
Mar 31, 2024
$36.12M
Aug 6, 2025
Q3
2025
Mar 31, 2024
$36.12M
Nov 6, 2025
Q3
2024
Sep 30, 2023
($40.94M)
Nov 6, 2024
Q2
2024
Jun 30, 2023
($23.94M)
Aug 7, 2024
Q3
2024
Jun 30, 2023
($23.94M)
Nov 6, 2024
Q3
2024
Mar 31, 2023
($516.76M)
Nov 6, 2024
Q2
2024
Mar 31, 2023
($516.76M)
Aug 7, 2024
Q1
2024
Mar 31, 2023
($516.76M)
May 1, 2024
Q3
2023
Sep 30, 2022
($257.74M)
Nov 1, 2023
Q2
2023
Jun 30, 2022
($231.48M)
Aug 2, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($103.39M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
$115.58M
Aug 6, 2025
Q1
2025
Mar 31, 2025
($300.39M)
May 6, 2025
Q3
2025
Sep 30, 2024
$22.20M
Nov 6, 2025
Q2
2025
Jun 30, 2024
($701.0K)
Aug 6, 2025
Q1
2025
Mar 31, 2024
$34.91M
May 6, 2025
Q3
2024
Sep 30, 2023
($20.84M)
Nov 6, 2024
Q2
2024
Jun 30, 2023
($133.52M)
Aug 7, 2024
Q1
2024
Mar 31, 2023
($138.09M)
May 1, 2024
Q3
2023
Sep 30, 2022
($131.36M)
Nov 1, 2023
Q2
2023
Jun 30, 2022
($211.13M)
Aug 2, 2023
Q1
2023
Mar 31, 2022
($86.88M)
May 2, 2023
Q3
2022
Sep 30, 2021
($34.46M)
Nov 2, 2022
Q2
2022
Jun 30, 2021
($167.57M)
Aug 2, 2022
Q1
2022
Mar 31, 2021
($151.87M)
May 4, 2022
Q3
2021
Sep 30, 2020
($137.07M)
Nov 3, 2021
Q2
2021
Jun 30, 2020
($138.35M)
Aug 4, 2021
Q1
2021
Mar 31, 2020
($118.03M)
May 5, 2021
Q3
2020
Sep 30, 2019
($123.59M)
Nov 5, 2020
Q2
2020
Jun 30, 2019
($275.37M)
Aug 5, 2020